| アブストラクト | Oxcarbazepine, a carbamazepine analog, was approved for use as an antiepileptic agent in the United States in 2000. A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of oxcarbazepine-associated angioedema in pediatric patients aged 16 years and younger. We describe in detail the first U.S. case report, of a 4(1/2)-year-old boy who experienced angioedema during treatment with oxcarbazepine. The reporting rate for angioedema was calculated to be 9.8 cases per 1,000,000 pediatric patients. Oxcarbazepine-associated angioedema manifested by swelling of the face, eyes, lips, or tongue or difficulty swallowing or breathing (or both) is a rare but potentially life-threatening reaction for which early recognition and management are vital. |
|---|
| ジャーナル名 | Pediatric neurology |
|---|
| 投稿日 | 2007/08/07 |
|---|
| 投稿者 | Knudsen, James F; Flowers, Charlene M; Kortepeter, Cindy; Awaad, Yasser |
|---|
| 組織名 | Office of Drug Evaluation I, Division of Neurology Products, Food and Drug;Administration, Silver Spring, Maryland 20993-0002, USA.;james.knudsen@fda.hhs.gov |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/17675030/ |
|---|
